Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in MS Patients. Case Series for Adjustment of Treatment Strategy and Its Monitoring

NCT01142453 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT01142453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01142453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in MS Patients. Case Series for Adjustment of Treatment Strategy and Its Monitoring
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Observational
Overall status
Completed
Start date
May 31, 2005
Completion date
June 30, 2008
Enrollment
231 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis